NCT02227992 - The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

October 27, 2021

Study Completion Date

November 12, 2021

Conditions

HemorrhageSoft Tissue BleedingHepatic Parenchyma Bleeding

Interventions

BIOLOGICAL

EVARREST™ Sealant Matrix

EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.

DEVICE

SURGICEL®

SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.

Trial Locations (10)

1020

Clinical Investigation Site #32, Brussels

Unknown

Investigative Site #30, Genk

Clinical Investigation Site #31, Ghent

Clinical Investigation Site #21, Birmingham

Clinical Investigation Site #22, Leeds

Clinical Investigation Site #20, Liverpool

Clinical Investigation Site #23, London

SE1 7EH

Clinical Investigation Site #26, London

NG7 2UH

Clinical Investigation Site #25, Nottingham

SO16 6YD

Clinical Investigation Site #24, Southampton

All Listed Sponsors

lead

Ethicon, Inc.

INDUSTRY